Real-time Estimate
Cboe BZX
15:30:51 03/05/2024 BST
|
5-day change
|
1st Jan Change
|
11.86
USD
|
+6.71%
|
|
+8.32%
|
-20.92%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
2,109
|
3,808
|
1,149
|
1,072
|
789
|
-
|
-
|
Enterprise Value (EV)
1 |
1,771
|
3,468
|
712
|
589.2
|
394.5
|
449.4
|
446.1
|
P/E ratio
|
-12.4
x
|
-22.6
x
|
-4.5
x
|
-3.39
x
|
-3.05
x
|
-2.95
x
|
-3.49
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
113
x
|
184
x
|
11.8
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
56.4
x
|
105
x
|
6.69
x
|
EV / EBITDA
|
-14.9
x
|
-16.1
x
|
-3.15
x
|
-1.98
x
|
-1.54
x
|
-1.56
x
|
-1.51
x
|
EV / FCF
|
-13.9
x
|
-16.9
x
|
-3.3
x
|
-2.83
x
|
-1.45
x
|
-1.43
x
|
-1.54
x
|
FCF Yield
|
-7.21%
|
-5.92%
|
-30.3%
|
-35.4%
|
-69.1%
|
-69.8%
|
-64.9%
|
Price to Book
|
6.91
x
|
10.5
x
|
2.75
x
|
2.45
x
|
2.33
x
|
3.01
x
|
3.3
x
|
Nbr of stocks (in thousands)
|
40,614
|
45,306
|
57,069
|
70,766
|
71,013
|
-
|
-
|
Reference price
2 |
51.94
|
84.06
|
20.14
|
15.15
|
11.11
|
11.11
|
11.11
|
Announcement Date
|
25/03/21
|
24/02/22
|
01/03/23
|
27/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
7
|
4.284
|
66.7
|
EBITDA
1 |
-
|
-118.6
|
-216
|
-225.9
|
-298.1
|
-256.9
|
-288.1
|
-294.9
|
EBIT
1 |
-
|
-118.8
|
-216.5
|
-227.3
|
-299.5
|
-273.6
|
-304.7
|
-284.2
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-3,908.44%
|
-7,112.05%
|
-426.14%
|
Earnings before Tax (EBT)
1 |
-
|
-118.1
|
-164.6
|
-221.3
|
-276.9
|
-263.5
|
-296.5
|
-262.3
|
Net income
1 |
-46.38
|
-118.5
|
-158.7
|
-236.8
|
-292.2
|
-270.3
|
-305.3
|
-287.1
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-3,861.92%
|
-7,126.66%
|
-430.51%
|
EPS
2 |
-8.160
|
-4.190
|
-3.720
|
-4.480
|
-4.470
|
-3.638
|
-3.770
|
-3.179
|
Free Cash Flow
1 |
-
|
-127.7
|
-205.3
|
-215.5
|
-208.4
|
-272.7
|
-313.6
|
-289.6
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-3,895.56%
|
-7,320.87%
|
-434.14%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
06/03/20
|
25/03/21
|
24/02/22
|
01/03/23
|
27/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
11.67
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-47.98
|
-
|
-
|
-
|
-51.4
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-62.87
|
-48.19
|
-57.88
|
-63.46
|
-54.19
|
-51.75
|
-64.95
|
-103.9
|
-62.72
|
-67.92
|
-55.6
|
-70.45
|
-72.33
|
-75.62
|
-71.92
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-476.57%
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-11.19
|
-48.1
|
-57.45
|
-63.04
|
-52.29
|
-48.52
|
-60.84
|
-99.46
|
-55.51
|
-61.07
|
-53.12
|
-66.9
|
-69.44
|
-74.22
|
-
|
Net income
1 |
-4.191
|
-50.06
|
-59.08
|
-68.36
|
-54.4
|
-54.97
|
-63.22
|
-112.5
|
-55.53
|
-60.92
|
-56.68
|
-67.97
|
-70.92
|
-74.93
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-485.87%
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.0900
|
-1.110
|
-1.310
|
-1.340
|
-0.9600
|
-0.9200
|
-1.070
|
-1.850
|
-0.7900
|
-0.8300
|
-0.7470
|
-0.9414
|
-0.9758
|
-0.9935
|
-0.7900
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
10/11/21
|
24/02/22
|
05/05/22
|
09/08/22
|
09/11/22
|
01/03/23
|
10/05/23
|
09/08/23
|
06/11/23
|
27/02/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
339
|
340
|
437
|
483
|
394
|
340
|
343
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-128
|
-205
|
-215
|
-208
|
-273
|
-314
|
-290
|
ROE (net income / shareholders' equity)
|
-
|
-104%
|
-47.2%
|
-59.4%
|
-67.1%
|
-62.2%
|
-103%
|
-124%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
7.520
|
8.000
|
7.320
|
6.180
|
4.780
|
3.690
|
3.370
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
0.76
|
6.11
|
2.55
|
0.58
|
1.96
|
2.8
|
3.95
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
28.06%
|
65.4%
|
5.93%
|
Announcement Date
|
06/03/20
|
25/03/21
|
24/02/22
|
01/03/23
|
27/02/24
|
-
|
-
|
-
|
Last Close Price
11.11
USD Average target price
35.6
USD Spread / Average Target +220.43% Consensus |
1st Jan change
|
Capi.
|
---|
| -20.92% | 789M | | -1.60% | 103B | | +7.14% | 101B | | +4.34% | 23.07B | | -13.09% | 22.23B | | -4.97% | 18.05B | | -39.98% | 17.18B | | -10.74% | 16.94B | | +6.57% | 14.07B | | +36.90% | 12.35B |
Bio Therapeutic Drugs
|